ロード中...
Dealing with hERG liabilities early: diverse approaches to an important goal in drug development
In drug development, early recognition of a potential for blocking the human ether-a-go-go related gene (hERG) channels is perhaps the best way to avoid later disappointment when QT interval prolongation shows up in clinical trials. Knowledge of the hERG blocking liability offers the chance to modif...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Blackwell Publishing Ltd
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2823348/ https://ncbi.nlm.nih.gov/pubmed/20141517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2009.00265.x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|